Samareh Azeredo da Silveira
Managing Director
Samareh is an early-stage drug development specialist. In 2007, she co-founded LASCCO SA, a virtual incubator dedicated to the identification of discovery-stage pharmaceuticals and diagnostics. Since then, she focused on the development of breakthrough technologies in the fields of critical care and infectious diseases. From 2011 to 2018, she was a partner at Sepstone Diagnostics, a spin-off of LASCCO, where she outlicensed a sepsis diagnostic technology to several industrial partners. She holds a PhD in Neurosciences from Ecole Polytechnique Fédérale de Lausanne (EPFL), and authored numerous publications and opinion reviews
Frédéric Lajaunias
Managing Director
Frédéric has over 10 years of experience in early stage development. In 2007, he co-founded LASCCO SA, a biomedical technology development company focusing on discovery-stage pharmaceuticals and diagnostics. Prior to founding LASCCO, Frédéric served at Abbott Laboratories as manager for the Swiss virology division. Before that, he carried out a post-doctoral work at the Geneva University Hospital studying autoimmune disorders.Frédéric holds a PhD in biology (immunology), from the University of Paris VII, and an MBA with a specialization in Entrepreneurship from the University of Geneva.
Toni Perez
Chief Medical Officer
Toni is a MD, specialist in Intensive Care, with diplomas of Pharmaceutical Industry and General Management Program. Prior to joining Combioxin, Toni was Head of Clinical Research of Infectious Diseases at Novartis, Head of Clinical Development of Anti-Infectives at Basilea Pharmaceutica, Area Head of Clinical Research in Oncology at Almirall, Medical Director of Gastro-intestinal track and CNS and a board member at Esteve. He is a consultant to several pharma companies. During is career, Toni has contributed to the development, registration and marketing of medicines in infectious diseases, oncology, CNS, and gastro-intestinal and urinary tracts among others.